The prohost effect of antimicrobial agents as a predictor of clinical outcome

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 1, 1997, Pages 100-108

  Labro, M T ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Clinical outcome; Host response; Immune response; Prohost effect; Synergism

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFODIZIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLOFAZIMINE; CYTOKINE; DAPSONE; DIRITHROMYCIN; ETHAMBUTOL; FOSFOMYCIN; GLYCOPEPTIDE; IMIPENEM; ISONIAZID; JOSAMYCIN; LINCOMYCIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; PEFLOXACIN; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; ROXITHROMYCIN; SULFONAMIDE; TETRACYCLINE; UNINDEXED DRUG;

ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CONFERENCE PAPER; DRUG EFFECT; HUMAN; IMMUNE RESPONSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGOCYTOSIS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIA; HUMANS; IMMUNE SYSTEM; MICROBIAL SENSITIVITY TESTS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 0030737810     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Labro MT. Host Defense and Infection. New York, Marcel Dekker, Inc. 1994: 1-68.
2. Ritts RE. Antibiotics as biological response modifiers. J Antimicrob Chemother 1991; 26 (suppl. C): 31-6.
3. Labro MT. Immunomodulation by antibacterial agents. Is it clinically relevant? Drugs 1993; 45: 319-28.
4. Gemmell CG. Antibiotics and neutrophil function-potential immunomodulating activities. J Antimicrob Chemothcr 1993; 31 (suppl. B); 23-33.
5. Labro MT. Interactions between antimicrobial drugs and phagocytes: an overview. Int J Antimicrob Agents 1993; 3: 73-87.
6. Labro MT. Effect of antimicrobial agents on polymorphonuclear neutrophil functions. In: Raoult D. ed. Antimicrobial. Agents and Intracellular Pathogens. Boca Raton, Ann Arbor, London, Tokyo CRC Press 1993: 87-135.
7. Barrett JF. The immunomodulatory activities of antibacterials. Exp Opin Invest Drugs 1995; 4: 551-7.
8. Labro MT. Immunomodulatory actions of antibacterial agents. Clin Immunother 1996; 6: 454-464.
9. Kawana M, Kawana C, Giebink GS. Penicillin-treatment accelerates middle ear inflammation in experimental pneumococcal otitis media. Infect Immun 1992; 60: 1908-12.
10. McConnell JS, Cohen J. Release of endotoxin from Escherichia coli by quinolones. J Antimicrob Chemother 1986; 18: 765-6.
11. Prins JM, Van Deventer SJH, Kuijper EJ, Speelman P. Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother 1994; 38: 1211-8.
12. Prins JM, Kuijper EJ, Mevissen MLCM, Speelman P, Van Deventer SJH. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun 1995; 63: 2236-42.
13. Yokoshi T, Kusumi A, Kido N et al. Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide. Antimicrob Agents Chemother 1996; 40: 2410-2.
14. Gemmell CG. Antibiotics and the expression of staphylococcal virulence. J Antimicrob Chemother 1995; 36: 283-91.
15. Hirakata Y, Kaku M, Mizukane R et al. Potential effects of erythromycin on host defence systems and virulence of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1992; 36: 1922-7.
16. Tateda K, Ishii Y, Matsumoto T et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2271-5.
17. Kobayashi H. Airway biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. J Infect Chemothcr 1995; 1: 1-15.
18. Silverstein SC, Kabbash C. Penetration, retention, intraccllular localization and antimicrobial activity of antibiotics within phagocytes. Curr Op Hematol 1994; 1: 85-91.
19. Labro MT. Intraphagocytic penetration of macrolide antibiotics. In: Bryskier A, Butzler JP, Neu HC, Tulkens PM (eds). Macrolides: Chemistry, Pharmacology and Clinical Uses. Paris, Arnette-Blackwell 1993: 379-88.
20. Labro MT. Intracellular bioactivity of macrolides. Clin Microb Infect 1996; 1 (suppl. 1): S24-S30.
21. Agouridas C, Benedetti Y, Denis A, Le Martret O, Chantot JF. Ketolides: a new distinct class of macrolide antibacterials. Synthesis and structural characteristics of RU 004. Program and Abstracts of the 35th Intersci Conf Antimicrob Agents Chemother 1995, Abstr. F-157.
22. Labro MT, Abdelghaffar H, Bryskier A. Characteristics of the cellular accumulation of RU 004 by human neutrophils (PMN). Comparison with azithromycin and roxithromycin. Program and Abstracts of the 36th Intersci Conf Antimicrob Agents Chemother 1996, Abstr. F-224.
23. Fassbender M, Lode H, Schiller C et al. Comparative pharmacokinetics of macrolide antibiotics and concentrations achieved in polymorphonuclear leukocytes and saliva. Clin Microbiol Infect 1996; 1: 235-43.
24. Bouvier d'Yvoire MJY, Tulkens PM. Computer-aided prediction of macrolide antibiotic concentrations in human circulating polymorphonuclear leucocytes. Program and Abstracts of the 7th Int Congr Infect Dis 1996, Abstr. 11480.
25. Schentag JJ. Tissue-directed pharmacokinetics. Am J Med 1991; 91 (suppl. 3A): 5S-18S.
26. Fontan PA, Buzzola FR, Spinedi EG, Sordelli DO. Haemophilus influenzae type b exoproducts induce chemotaxis and macrolide antibiotic release by human polymorphonuclear leukocytes. Chemotherapy 1996; 42: 71-7.
27. Labro MT. Effects of macrolides on host natural defenses. In: Bryskier A, Butzler JP, Neu HC, Tulkens PM (eds). Macrolides: Chemistry, Pharmacology and Clinical Uses. Paris, Arnette-Blackwell 1993: 389-408.
28. Labro MT. Effects of macrolides on leukocytes and inflammation. In: Zinner S, Young Y, Acar J (eds). Expanding indications for the new macrolides, azalides and streptogramins. New York: Marcel Dekker 1996: 101-16.
29. Fujii T, Kadota JI, Morikawa T et al. Inhibitory effect of erythromycin on interleukin-8 production by 1α, 25-dihydroxyvitamin D3-stimulated THP1-cells. Antimicrob Agents Chemother 1996; 40: 1548-51.
30. Oishi K, Sonoda F, Kobayashi S et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145-52.
31. Sakito O, Kadota JI, Kohno S, Abe K, Shirai R, Hara K. Interleukin-1β, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42-8
32. Wenish C, Parschalk B, Zedtwitz-Liebenstein K, Weihs A, El Menyawi I, Graninger W. Effect of single oral dose of azithromycin, clarithromycin, and roxithromycin on polymorphonuclear function assessed ex vivo by flow cytometry. Antimicrob Agents Chemother 1996; 40: 2939-42.
33. Labro MT. Resistance to and immunomodulation effects of cephalosporin antibiotics. Clin Drug Invest 1995; 9 (suppl. 3): 31-44.
34. Lapenna D, Cellini L, De Gioia S et al. Cephalosporins are scavengers of hypochlorous acid. Biochem Pharmacol 1995; 49: 1249-54.
35. Labro MT. Cefodizime as a biological response modifier: a review of its in-vivo, ex-vivo and in-vivo immunomodulatory properties. J Antimicrob Chemother 1990; 26 (suppl. C): 37-47.
36. Meloni F, Ballabio P, Bianchi L, Grassi FA, Gialdroni-Grassi G. Cefodizime modulates in vitro tumor necrosis factor alpha, interleukin-6 and interleukin-8 release from human peripheral monocytes. Chemotherapy 1995; 41: 289-95.
37. Pacheco Y, Hosni R, Dagrosa EE et al. Antibiotics and production of granulocyte-macrophage colony stimulating factor by human bronchial epthelial cells in vitro. Arzneim Forsch 1994; 44: 559-63.
38. Shin WS, Min CK, Kim YR, Yoo JH, Kang MW. In-vitro effects of cefodizime on leucocyte functions and colony formation from granulocyte-macrophage progenitors. J Antimicrob Chemother 1996; 37: 93-103.
39. Wenisch C, Parschalk B, Hasenhünd M, Wiesinger E, Graninger W. Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections. Antimicrob Agents Chemother 1995; 39: 672-6.
40. Shapira L, Soskolne WA, Houri Y, Barak V, Halabi A, Stabholz A. Protection against endotoxic shock and lipopolysacchariade-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun 1996; 64: 825-8.
41. Morikawa K, Watabe H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 1996; 40: 1366-70.
42. Neftel KA, Mauser SP, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by β-lactam antibiotics. J Infect Dis 1985; 152: 90-8.
43. Tantawichien T, Tungsanga K, Swasdikul D. Reversible severe neutropenia after ceftriaxone. Scand J Infect Dis 1994; 26: 109-10.
44. Charak BS, Brown EG, Mazumder A. Role of granulocyte colony-stimulating factor in preventing ceftazidime-induced myelosuppression in vitro. Bone Marrow Transplant 1995; 15: 749-55.
45. Hahn T, Barak Y, Liebovich E, Malach L, Dagan O, Rubinstein E. Ciprofloxacin inhibits human hematopoietic cell growth: synergism with tumor necrosis factor and interferon. Exp Hematol 1991; 19: 157-60.
46. Kletter Y, Singer A, Nagher A, Slavin S, Fabian I. Ciprofloxacin enhances hematopoiesis and the peritoneal neutrophil function in lethally-irradiated, bone-marrow-transplanted mice. Exp Hematol 1994; 22: 360-5.
47. Patchen ML, Brook I, Elliott TB, Jackson WE. Adverse effects of pefloxacin in irradiated C3H/He N mice: correction with glucan therapy. Antimicrob Agents Chemother 1993; 37: 1882-5.
48. Moulder JW. Comparative biology of intracellular parasitism. Microbiol Rev 1995; 49: 298-337.
49. Bakker-Woudenberg IAJM. Delivery of antimicrobials to infected tissue macrophages. Adv Drug Delivery Rev 1995; 17: 5-20.
50. Couvreur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharmaceut Res 1991; 8: 1079-86.